Prothrombotic effects of erythrocytes on platelet reactivity: Reduction by aspirin

Circulation

Volumn 95, Issue 1, 1997, Pages 63-68

  Santos, M Teresa ^a   Valles, Juana ^a   Aznar, Justo ^a   Marcus, Aaron J ^b,c   Broekman, M Johan ^b   Safier, Lenore B ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

aspirin; cardiovascular diseases; erythrocytes; platelets; thrombosis; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; PROSTACYCLIN; THROMBOXANE A2;

ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; ERYTHROCYTE; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

EID: 0031013712     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.1.63     Document Type: Article

References (26)

1. AntiPlatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J. 1988; 296:320-331.
2. AntiPlatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994:308:81-106.
3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994; 330:1287-1294.
4. Prentice CRM. Antithrombotic therapy in the secondary prevention of myocardial infarction. Am J Cardiol. 1993;72:175G-180G.
5. Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the United States. Arch Intern Med. 1994;154:37-39.
6. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177-1184.
7. Kearon C, Hirsh J. Optimal dose for starting and maintaining low-dose aspirin. Arch Intern Med. 1993;153:700-702.
8. Marcus AJ. Platelets and their disorders. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. 3rd ed. Philadelphia, Pa: WB Saunders. 1996:79-137.
9. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. 2nd ed. New York, NY: Raven Press; 1992:219-273.
10. Perez-Requejo JL, Aznar J, Santos MT, Valles J. Early platelet-collagen interactions in whole blood and their modifications by aspirin and dipyridamole evaluated by a new method (Basic Wave). Thromb Haemost. 1985;54:799-803.
11. Santos MT, Valles J, Aznar J, Perez-Requejo JL. Role of red blood cells in the early stage of platelet activation by collagen. Thromb Haemost. 1986;56:376-381.
12. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest. 1991;87:571-580.
13. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, Broekman MJ, Safier LB. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. Blood. 1991;78:154-162.
14. Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Aznar J. Down-regulation of human platelet reactivity by neutrophils: participation of lipoxygenase derivatives and adhesive proteins. J Clin Invest. 1993;92:1357-1365.
15. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 1993;7:516-522.
16. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol. 1994;31:261-269.
17. Marcus AJ. Eicosanoid interactions between platelets, endothelial cells, and neutrophils. Methods Enzymol. 1990;187:585-598.
18. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
19. Weksler BB, Kent JL, Rudolph D, Scherer PB, Levy DE. Effects of low-dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke. 1985;16:5-9.
20. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol. 1985;60:635-642.
21. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250, 310-318.
22. Marcus AJ, Safier LB, Broekman MJ, Islam N, Fliessbach JH, Hajjar KA, Kaminski WE, Jendraschak E, Silverstein RL, von Schacky C. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost. 1995;74:213-217.
23. Ruggeri ZM. The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Thromb Haemost. 1995:74:460-463.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
25. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell. 1986:46:155-169.
26. Marcus AJ. Pathogenesis of atherosclerosis: special pathogenetic factor-inflammation and immunity: platelets. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Disease. Philadelphia, Pa: Lippincott-Raven; 1996:607-637.